COVID-19: dealing with a potential risk factor for chronic neurological disorders
- PDF / 636,352 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 61 Downloads / 156 Views
REVIEW
COVID‑19: dealing with a potential risk factor for chronic neurological disorders Tommaso Schirinzi1 · Doriana Landi2 · Claudio Liguori3,4 Received: 12 June 2020 / Revised: 28 July 2020 / Accepted: 29 July 2020 © The Author(s) 2020
Abstract SARS-CoV2 infection is responsible for a complex clinical syndrome, named Coronavirus Disease 2019 (COVID-19), whose main consequences are severe pneumonia and acute respiratory distress syndrome. Occurrence of acute and subacute neurological manifestations (encephalitis, stroke, headache, seizures, Guillain–Barrè syndrome) is increasingly reported in patients with COVID-19. Moreover, SARS-CoV2 immunopathology and tissue colonization in the gut and the central nervous system, and the systemic inflammatory response during COVID-19 may potentially trigger chronic autoimmune and neurodegenerative disorders. Specifically, Parkinson’s disease, multiple sclerosis and narcolepsy present several pathogenic mechanisms that can be hypothetically initiated by SARS-CoV2 infection in susceptible individuals. In this short narrative review, we summarize the clinical evidence supporting the rationale for investigating SARS-CoV2 infection as risk factor for these neurological disorders, and suggest the opportunity to perform in the future SARS-CoV2 serology when diagnosing these disorders. Keywords Parkinson’s disease · Multiple sclerosis · Narcolepsy · SARS-CoV2 · COVID-19 · Neuroinflammation · Risk factors · Neurodegeneration · Demyelination · Sleepiness
Introduction
Tommaso Schirinzi, Doriana Landi and Claudio Liguori have equally contributed to manuscript conceptualization and drafting, and equally serve as corresponding authors. * Tommaso Schirinzi [email protected] * Doriana Landi [email protected] * Claudio Liguori [email protected] 1
Neurology Unit, University Hospital of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
2
Multiple Sclerosis Clinical and Research Unit, University Hospital of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
3
Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, 81, 00133 Rome, Italy
4
Neurology Unit, University Hospital of Rome Tor Vergata, Viale Oxford, 81, 00133 Rome, Italy
In December 2019, a novel coronavirus, named severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2), emerged from China and spread worldwide as pandemic. SARS-CoV2 infection is responsible for a heterogeneous clinical syndrome, leading to severe pneumonia and acute respiratory distress syndrome (ARDS), titled coronavirus disease 2019 (COVID-19). The occurrence of neurological manifestations, including encephalitis, stroke, headache, seizures, Guillain–Barrè syndrome, is increasingly reported in patients with COVID-19 [1–4]. Although these neurological manifestations of COVID-19 suggest a possibly acute or subacute neuropathogenicity of the virus, the risk of longterm neurological sequelae in patients affected by SARSCoV2 is not understood and currently debated [5, 6]
Data Loading...
